# Questions and Answers on Biosimilar Development and the BPCI Act:  Guidance for Industry – FDA Guidance

Source: https://www.keypedia.com/guidances/guidance-document/questions-and-answers-on-biosimilar-development-and-the-bpci-act-guidance-for-industry/694a2c54-b987-4bc2-8305-dfe605c5d842

> FDA guidance document: Questions and Answers on Biosimilar Development and the BPCI Act:  Guidance for Industry. Issue date: March 09, 2026. Get complete insights and analysis.

---

## Details

- Title: Questions and Answers on Biosimilar Development and the BPCI Act:  Guidance for Industry
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2026-03-09
- Last Changed: 2026-03-09
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2011-D-0611">FDA-2011-D-0611</a>

## Related Documents

- [Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers](https://www.keypedia.com/guidances/guidance-document/postapproval-manufacturing-changes-to-biosimilar-and-interchangeable-biosimilar-products-questions-and-answers/f3f2a490-2ac9-47b1-82ca-d3a550511aaf)
- [Questions and Answers on Biosimilar Development and the BPCI Act:  Guidance for Industry](https://www.keypedia.com/guidances/guidance-document/questions-and-answers-on-biosimilar-development-and-the-bpci-act-guidance-for-industry/d8b2afc2-4d89-4b73-8d18-023369abff5b)
- [Q8, Q9, and Q10 Questions and Answers (R5)](https://www.keypedia.com/guidances/guidance-document/q8-q9-and-q10-questions-and-answers-r5/0d8061f0-c7e5-49c2-8e30-7202d91074f1)